Jonathan D Winter1, John William Kerns2, Katherine M Winter3, Alicia Richards4, Roy T Sabo4. 1. VCU-Shenandoah Family Practice Residency (JDW, JWK, KMW), Front Royal, VA; Department Biostatistics, Department of Family Medicine and Population Health (JDW, JWK, AR, RTS), Virginia Commonwealth University, Richmond, VA. Electronic address: jwinter@valleyhealthlink.com. 2. VCU-Shenandoah Family Practice Residency (JDW, JWK, KMW), Front Royal, VA; Department Biostatistics, Department of Family Medicine and Population Health (JDW, JWK, AR, RTS), Virginia Commonwealth University, Richmond, VA. 3. VCU-Shenandoah Family Practice Residency (JDW, JWK, KMW), Front Royal, VA. 4. Department Biostatistics, Department of Family Medicine and Population Health (JDW, JWK, AR, RTS), Virginia Commonwealth University, Richmond, VA.
Abstract
OBJECTIVE: Excluded from reporting to CMS's Percentage of long-stay residents who got an antipsychotic medication quality-measure are antipsychotics prescribed to nursing home patients with schizophrenia, Tourette's, or Huntington's. Over the 4 years following its 2012 debut, the quality-measure calculated a 27% reduction in inappropriate antipsychotic use but also an 18.3% increase in exclusion claims. This study evaluated the impact of these exclusions on the measure's findings. METHODS: Claims data for the years 2011-2016 retrospectively identified the prevalence of schizophrenia, Tourette's, and Huntington's in quarterly cohorts of Virginia long-stay residents prescribed antipsychotics. Annualized diagnoses in 2011 were compared with subsequent years using simple logistic regression. RESULTS: In 2016, 29% of the antipsychotics prescribed in Virginia nursing homes were to residents with diagnoses of schizophrenia, Tourette's, and Huntington's, a significant 32% increase from 2011. CONCLUSION: Almost 30% of the antipsychotics employed in Virginia nursing homes are excluded from CMS's long-stay antipsychotic quality-measure.
OBJECTIVE: Excluded from reporting to CMS's Percentage of long-stay residents who got an antipsychotic medication quality-measure are antipsychotics prescribed to nursing home patients with schizophrenia, Tourette's, or Huntington's. Over the 4 years following its 2012 debut, the quality-measure calculated a 27% reduction in inappropriate antipsychotic use but also an 18.3% increase in exclusion claims. This study evaluated the impact of these exclusions on the measure's findings. METHODS: Claims data for the years 2011-2016 retrospectively identified the prevalence of schizophrenia, Tourette's, and Huntington's in quarterly cohorts of Virginia long-stay residents prescribed antipsychotics. Annualized diagnoses in 2011 were compared with subsequent years using simple logistic regression. RESULTS: In 2016, 29% of the antipsychotics prescribed in Virginia nursing homes were to residents with diagnoses of schizophrenia, Tourette's, and Huntington's, a significant 32% increase from 2011. CONCLUSION: Almost 30% of the antipsychotics employed in Virginia nursing homes are excluded from CMS's long-stay antipsychotic quality-measure.
Authors: Patience Moyo; Emily Corneau; Portia Y Cornell; Amy L Mochel; Kate H Magid; Cari Levy; Vincent Mor Journal: Int J Methods Psychiatr Res Date: 2021-11-05 Impact factor: 4.035